NeuClone Starts Trial For Ustekinumab Biosimilar
NeuLara Rival To Stelara Enters Phase I Clinical Trial
After extensive pre-clinical testing, NeuClone has commenced dosing in a Phase I clinical trial for its Stelara biosimilar candidate, NeuLara.
You may also be interested in...
Neuclone Makes Progress With Ustekinumab Trial
Australia’s NeuClone has reported the completion of subject visits in its Phase I trial for a biosimilar ustekinumab rival to Janssen’s Stelara, with favorable results seen ahead of the formal study report that is due in the third quarter of this year.
Meiji And Dong-A Start European Ustekinumab Trial
A Phase I study will compare the pharmacokinetics, safety and tolerability of Meiji and Dong-A’s DMB-3115 ustekinumab biosimilar candidate against Janssen’s Stelara reference psoriasis and Crohn’s disease brand.
Bio-Thera Gets Chinese Nod To Proceed On Ustekinumab
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.